Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-020-2423-5 http://scihub22266oqcxt.onion/10.1038/s41586-020-2423-5 32516797!7486271!32516797     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2020 ; 585 (7824): 273-276 Nephropedia Template TP {{tp|p=32516797|t=2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 |pdf=|usr=}}{{32516797}} gab.com Text Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=32516797 #FOAvip Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed. While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclinical data from animal models can guide the search for effective treatments by ruling out those that lack efficacy in vivo. Remdesivir (GS-5734) is a nucleotide analogue prodrug with broad antiviral activity(1,2) that is currently being investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration(3,4). In animal models, remdesivir was effective against infection with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)(2,5,6). In vitro, remdesivir inhibited replication of SARS-CoV-2(7,8). Here we investigate the efficacy of remdesivir in a rhesus macaque model of SARS-CoV-2 infection(9). Unlike vehicle-treated animals, macaques treated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary infiltrates on radiographs and reduced virus titres in bronchoalveolar lavages twelve hours after the first dose. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment. At necropsy, remdesivir-treated animals had lower lung viral loads and reduced lung damage. Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2. Although the rhesus macaque model does not represent the severe disease observed in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia. Twit Text FOAVip Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=32516797 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32516797 #FOAvip English Wikipedia <ref>{{Cite pmid|32516797}}</ref> Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 #MMPMID32516797 Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Perez-Perez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E Nature 2020[Sep]; 585 (7824): 273-276 PMID32516797show ga Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed. While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclinical data from animal models can guide the search for effective treatments by ruling out those that lack efficacy in vivo. Remdesivir (GS-5734) is a nucleotide analogue prodrug with broad antiviral activity(1,2) that is currently being investigated in COVID-19 clinical trials and recently received Emergency Use Authorization from the US Food and Drug Administration(3,4). In animal models, remdesivir was effective against infection with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)(2,5,6). In vitro, remdesivir inhibited replication of SARS-CoV-2(7,8). Here we investigate the efficacy of remdesivir in a rhesus macaque model of SARS-CoV-2 infection(9). Unlike vehicle-treated animals, macaques treated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary infiltrates on radiographs and reduced virus titres in bronchoalveolar lavages twelve hours after the first dose. Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment. At necropsy, remdesivir-treated animals had lower lung viral loads and reduced lung damage. Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2. Although the rhesus macaque model does not represent the severe disease observed in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia. |*Disease Models, Animal[MESH] |Adenosine Monophosphate/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use[MESH] |Alanine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use[MESH] |Animals[MESH] |Betacoronavirus/*drug effects/genetics/pathogenicity[MESH] |Bronchoalveolar Lavage Fluid/virology[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/pathology/physiopathology/*virology[MESH] |DNA Mutational Analysis[MESH] |Disease Progression[MESH] |Drug Resistance, Viral[MESH] |Female[MESH] |Lung/drug effects/pathology/physiopathology/virology[MESH] |Macaca mulatta/*virology[MESH] |Male[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/pathology/physiopathology/*prevention & control/virology[MESH] |SARS-CoV-2[MESH] |Secondary Prevention[MESH] |Time Factors[MESH] |Viral Load/drug effects[MESH] |Virus Replication/drug effects[MESH]Clinical benefit of remdesivir in rhesus macaques infected with SARS-C(epmc).pdf DeepDyve Pubget Overpricing